deltatrials
Completed PHASE2 NCT00101985

Eight-Weeks Of Treatment With Talnetant In Subjects With Irritable Bowel Syndrome (IBS)

An Eight-week, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate Efficacy and Safety of Talnetant in Subjects With Irritable Bowel Syndrome

Sponsor: GlaxoSmithKline

Conditions Irritable Colon
Interventions talnetant
Updated 6 times since 2017 Last updated: Apr 10, 2015 Started: Oct 31, 2004 Primary completion: Jul 31, 2005 Completion: Jul 31, 2005

This PHASE2 trial investigates Irritable Colon and is currently completed. GlaxoSmithKline leads this study, which shows 6 recorded versions since 2004 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Oct 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia, Akron, United States, Atlanta, United States, Austin, United States, Bad Segeberg, Germany, Badalona, Spain, Barcelona, Spain, Bedford Park, Australia, Berlin, Germany, Blackpool, United Kingdom and 110 more location s